Targeted alpha therapy using Radium-223: From physics to biological effects

Area of Science:

• Nuclear medicine and radiation oncology.
• Molecular biology and cancer research.

Background:

• Targeted alpha therapy (TAT) is an emerging cancer treatment modality utilizing alpha-emitting radionuclides.
• It aims to maximize radiation effects on tumor cells while minimizing damage to surrounding healthy tissues.
• Radium-223 (²²³Ra) is an approved TAT agent for bone metastasis in prostate cancer, but its precise molecular mechanisms remain unclear.

Purpose of the Study:

• To review the physical properties of TAT and their correlation with observed radiobiological effects.
• To link TAT's mechanisms to the established hallmarks of cancer.
• To consolidate existing research on ²²³Ra in the context of TAT, radiobiology, and cancer hallmarks.

Main Methods:

• Literature review and synthesis of existing studies on targeted alpha therapy.
• Analysis of physical characteristics of alpha emitters and their biological consequences.
• Correlation of TAT properties with the '5 Rs of radiobiology' and cancer hallmarks.

Main Results:

• The review establishes a connection between TAT's physical properties and its radiobiological impact.
• It highlights how TAT influences key cancer hallmarks.
• Studies involving ²²³Ra are discussed in relation to these established frameworks.

Conclusions:

• Understanding the molecular interactions of TAT is crucial for optimizing its therapeutic efficacy.
• This review provides a framework for understanding TAT's role in cancer treatment.
• ²²³Ra shows significant promise, and further research into its mechanisms is warranted.